Scailyte AG is a spin-off from ETH Zurich combining single-cell technologies, high-quality clinical datasets and machine learning methods to identify ultra-sensitive biomarkers in oncology and immunology. We have developed ScaiVision – a best-in-class single-cell data analysis platform for biomarker discovery and AI-driven clinical applications. ScaiVision can analyse various single-cell data types (DNA-/RNA-/TCR-/BCR-seq, CITE-seq, proteomics, mass & flow cytometry ) in combination with physiological and clinical parameters. We have multiple patent-pedning biomarkers and a growing pipeline of discovery and co-development projects with leading medical Universities and biotech companies.
For more information, go to https://scailyte.com and connect via @LinkedIn